Is Verano the New Must Own Cannabis Stock
Is Verano a solid addition to any Cannabis Portfolio? We’ve gone digging to find out.
Read More»
Aphria Offers Big Upside if the Tilray Deal Closes
Aphria offers 90% upside, but this return won’t come for free
Read More»
Locked & Lit: The Grizzle Cannabis Portfolio
See how Grizzle invests in the emerging cannabis industry. Our proprietary portfolio revealed.
Read More»WITH CHRISTOPHER WOOD
Internationally renowned for his salient predictions of market bubbles, Chris provides global investment insights in his weekly column 'Macro Battleship'.
Dutch Bros Coffee is Starbucks for the Next Generation
Dutch Bros is Starbucks for the next generation. Learn what it does different and more importantly what its worth.
Read More»
Weber vs Traeger: Who Makes the Best Grill and the Best Stock?
We compare and contrast Traeger and Weber to see which IPO is worth your money.
Read More»
Corsair Gaming is on the Move and You Shouldn’t be Surprised.
Corsair is running and those who followed the Stock Safari Newsletter knew to hop on board back in April.
Read More»
Trulieve CEO Kim Rivers Doesn’t Need Debt to Grow
Kim Rivers talks catalysts, why she doesn’t like debt and where future growth is going to come from in this exclusive interview.
Read More»
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Apr 25th, 2020)
A weekly review of only the most important cannabis news to impact your portfolio
Read More»
Organigram Announces $49M At-The-Market Equity Program
As we feared and warned investors about earlier, the company has announced today that it is doing a at-the-market equity raise program valued at $49M.
Read More»
Robinhood is Now a Meme, But More Important is What Comes Next?
The IPO day is just a circus, what really matters is where the stock will go over the weeks and months ahead.
Read More»
Etsy Q1 Earnings: Is the COVID-19 Growth Gone?
Etsy guided to a much slower 2021 than investors were expecting. Can the stock rebound from this dissapointment?
Read More»PSYCHEDELICS
Why Compass Pathways (CMPS) is a 5-bagger: $210/share
Grizzle outlines the structural share price upside of Compass Pathways and its psilocybin drug: COMP 360 to treat depression.
Read More»
The Most Anticipated Psychedelic IPO: Compass Pathways (CMPS)
Grizzle sits down with Terry Chong (Partner, Grizzle Venture) to discuss one of the most anticipated psychedelic IPOs: Compass Pathaways
Read More»
Grizzle Twitter
AS FEATURED ON
